` 603590 (Beijing Konruns Pharmaceutical Co Ltd) vs Shanghai Composite Comparison - Alpha Spread

603590
vs
S
Shanghai Composite

Over the past 12 months, Beijing Konruns Pharmaceutical Co Ltd has significantly outperformed Shanghai Composite, delivering a return of +83% compared to the Shanghai Composite's +25% growth.

Stocks Performance
603590 vs Shanghai Composite

Loading
603590
Shanghai Composite
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
603590 vs Shanghai Composite

Loading
603590
Shanghai Composite
Difference
www.alphaspread.com

Performance By Year
603590 vs Shanghai Composite

Loading
603590
Shanghai Composite
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Beijing Konruns Pharmaceutical Co Ltd vs Peers

Shanghai Composite
603590
LLY
JNJ
ROG
AZN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Beijing Konruns Pharmaceutical Co Ltd
Glance View

Market Cap
6.6B CNY
Industry
Pharmaceuticals

Beijing Konruns Pharmaceutical Co., Ltd. engages in the research, development, production, and marketing of new drugs, with a focus on new special drugs. The company is headquartered in Beijing, Beijing and currently employs 473 full-time employees. The company went IPO on 2018-08-27. The firm's main product Suling belongs to the haemocoagulase drug that activates the coagulation process, which is mainly used for hemostasis of superficial wound bleeding in surgical operations as well as the bleeding caused by postoperative, trauma and disease. The Company’s present products under research include a range of innovative and generic drugs for tumors and blood. The firm mainly distributes its products in the domestic market.

Intrinsic Value
44.84 CNY
Undervaluation 8%
Intrinsic Value
Price
Back to Top